A Alaska overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Alaska's adult obesity rate was 34.0% in 2024 — essentially flat versus 35.2% the year before, but up 4.2 percentage points from 29.8% in 2015 6. The 2024 figure was independently re-derived at 33.98% crude prevalence (95% CI 31.98–35.98%, n=1,687) from CDC BRFSS dataset dttw-5yxu, an exact match 7.
Applied to 740,133 residents 8 spread across the largest state in the country, the practical question is less about prevalence than about distance and coverage.
Alaska Medicaid's Preferred Drug List, effective 6/1/2026, places GLP-1/incretin agents only under PDL Group A, "Hypoglycemics, Incretin Mimetics/Enhancers" — the type-2-diabetes class. Ozempic, Rybelsus, Trulicity, and Victoza are preferred; generic liraglutide, Mounjaro, and Xultophy are non-preferred. Wegovy, Saxenda, and Zepbound — the three GLP-1/GIP products FDA-labeled specifically for chronic weight management — do not appear anywhere in the 47-page list 12.
The state's Prior Authorization criteria library tells the same story from the other side: Alaska Medicaid publishes detailed PA criteria for Imcivree (setmelanotide) — updated 12/23/2025, effective 3/1/2026 — but restricts it to rare monogenic and syndromic obesity (Bardet-Biedl syndrome, POMC/PCSK1/LEPR deficiency), and publishes no PA-criteria document at all for Wegovy, Saxenda, or Zepbound 345.
Read together, these two official, dated documents indicate Alaska Medicaid covers GLP-1/GIP receptor agonists for their FDA-approved diabetes indication, not for obesity treatment. That conclusion is drawn from what two primary documents omit, not from one line stating an exclusion outright — the state's consumer-facing Medicaid drug-coverage page and its PBM's interactive lookup tool were both unreachable for independent confirmation this pass (a Cloudflare bot-check on one, a JS-only tool on the other). Treat this as a well-sourced inference pending a direct portal or phone check, not a final word from the state.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Median household income in Alaska is $95,665 (ACS 2024 1-year estimate) 10. Alaska's uninsured rate was not obtained in this research pass and is deliberately left blank rather than estimated.
Alaska has 338 active federally designated Primary Care Health Professional Shortage Areas statewide, 300 of them (89%) in rural areas, per HRSA's Bureau Common Data HPSA export, most recently updated 6/25/2026 9.
With most of Alaska's primary-care shortage areas outside its cities, in-person access to a weight-management specialist is thin across much of the state. A telehealth prescriber removes a drive that, in rural Alaska, is often measured in hours, not minutes.
Licensing and telehealth authority for prescribers treating Alaska residents sits with the Alaska State Medical Board 11.
TODO — unverified: the board's specific telehealth and GLP-1 prescribing rules were not confirmed in this research pass (the site returned an error to automated access), so this page states none. Do not treat the board link as a confirmed source of Alaska telehealth rules until it is read directly.
Astra treats patients in Alaska and in all 50 states. Care is delivered entirely online, which is the point in a state where the nearest specialist may be a flight away.
Astra treats patients in Alaska through state-licensed physicians.
Anchorage has its own page in progress. City-level obesity, HPSA, and local pricing data for Anchorage have not been gathered yet, and nothing on that page will be published until they are.
Not based on the state's published Preferred Drug List and Prior Authorization criteria as of this review. Alaska Medicaid's PDL (effective 6/1/2026) places GLP-1/incretin drugs only in the type-2-diabetes class, and none of the three products FDA-labeled for weight management appear in it; the state's PA-criteria library has no document for any of the three either. Alaska Medicaid does publish PA criteria for Imcivree, but only for rare genetic forms of obesity. This is an inference from two official documents rather than one explicit exclusion statement, so confirm directly with Alaska Medicaid before assuming your specific plan follows this pattern.
No — and it isn't more expensive either. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan ($816 and $1,416 billed annually) in every state it serves, Alaska included. There's no Alaska markup and no Alaska discount.
Alaska has 338 federally designated primary-care shortage areas, and 89% of them are rural. A telehealth visit doesn't require driving to one of the state's few weight-management specialists — which matters most in the parts of Alaska where that drive is measured in hours.
Astra's price is $68/month for semaglutide or $118/month for tirzepatide, billed on a 12-month plan ($816 or $1,416 total). That's the national price — it applies the same way for Alaska patients as for patients in any other state Astra serves.
Yes. Astra is licensed to treat patients in all 50 states, including Alaska.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.